CTTQ-Akeso Biomed Tech

CTTQ-Akeso is a joint venture between Chia Tai Tianqing Pharmaceutical Group and Akeso, Inc., established to develop and commercialize the anti-PD-1 monoclonal antibody penpulimab. The company combines Akeso's advanced antibody discovery platform with Chia Tai Tianqing's robust commercialization infrastructure in China. Its lead product, penpulimab (Annike), is approved in China for indications including classical Hodgkin lymphoma and squamous non-small cell lung cancer. The venture focuses on expanding the clinical utility of penpulimab through various combination therapies in oncology. By leveraging the strengths of both parent companies, CTTQ-Akeso aims to provide high-quality, accessible immunotherapy options to patients. The company is headquartered in Shanghai and operates as a key strategic entity within the Chinese biopharmaceutical landscape.